HbO2 Therapeutics

Executive Summary

HbO2 Therapeutics is a biotech company specializing in hemoglobin-based oxygen carriers (HBOCs) to treat tissue hypoxia and ischemia. Its lead product, Hemopure, is approved in South Africa and Russia for acute anemia in surgical patients and is available in the US under an FDA Expanded Access Program. The company also markets Oxyglobin, an FDA and EMA-approved veterinary HBOC for canine anemia. These approvals validate the platform's ability to deliver oxygen without donor blood, addressing critical needs in trauma, surgery, and emergency medicine where blood transfusions are unavailable or contraindicated. Despite having marketed products, the company's stage is listed as pre-clinical, likely reflecting development of next-generation HBOCs or new indications. HbO2 Therapeutics aims to expand its regulatory footprint globally and pursue additional clinical applications, such as traumatic hemorrhage and ischemic stroke. The technology has potential to revolutionize oxygen therapeutics by providing a universal, stable, and pathogen-free alternative to blood transfusions. Ongoing efforts focus on US regulatory pathways and broadening adoption in underserved regions. The company's progress in securing approvals and real-world use under Expanded Access suggests a viable path to commercialization, though further clinical data will be critical for major market entries.

Upcoming Catalysts (preview)

• Q3 2026FDA meeting or submission for Hemopure in the US40% success
• Q4 2026New clinical trial initiation for traumatic hemorrhage indication50% success
• TBDPartnership or licensing deal for global distribution of Hemopure60% success